Faldaprevir's efficacy in Asian HCV patients looking good
This article was originally published in Scrip
Executive Summary
A new analysis of data from Boehringer Ingelheim's STARTVerso suite of ongoing Phase III international studies with faldaprevir (BI 201335) in patients with chronic hepatitis C virus (HCV) infection show high rates of efficacy for the protease inhibitor in Northeast Asian patients.